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Abstract
While the symptomology of underactive bladder (UAB) may imply a primary dysfunction of the 
detrusor muscle, insights into pathophysiology indicate that both myogenic and neurogenic 
mechanisms need to be considered. Due to lack of proper animal models, the current 
understanding of the UAB pathophysiology is limited, and much of what is known about the 
clinical etiology of the condition has been derived from epidemiological data. We hereby review 
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current state of the art in the understanding of the pathophysiology of and animal models used to 
study the UAB.
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Introduction
International Continence Society defines detrusor underactivity/underactive bladder as a 
detrusor contraction of inadequate strength and/or duration, resulting in prolonged bladder 
emptying and/or a failure to achieve complete bladder emptying in the absence of urethral 
obstruction. Prevalence of urodynamically confirmed underactive bladder (UAB) is in 9–48 
% of men and 12–45 % of older women having non-neurogenic lower urinary tract 
symptoms [1, 2].
Bladder emptying requires complete relaxation of the internal (smooth muscle) and external 
(striated muscle) urethral sphincter followed by increased intravesical pressure due to 
detrusor smooth muscle contraction. The transition from filling phase to emptying phase of 
the lower urinary tract occurs voluntarily in healthy adults. Neurons from the brain and the 
spinal cord align together to form a neural control system to coordinate the reciprocal 
activity of two functional motor units involved in bladder emptying that is the detrusor and 
the outlet formed by the bladder neck, urethra and striated muscles of the urethral sphincter 
[3]. Neuron reflexes guiding the voiding are mediated by a spinobulbospinal pathway 
passing through a coordination center [the pontine micturition center (PMC)] located in the 
brain stem [3], which sets the volume at which the lower urinary tract switches from filling 
to emptying mode, thereby effectively determining maximum bladder capacity. The reflexes 
responsible for the bladder filling are organized at the spinal cord level with inputs from 
brainstem and cerebral centers [4].
Activation and maintenance of the micturition reflex is dependent upon normal relay of 
afferent information from the bladder to higher brain centers. Afferents convey the sensation 
of bladder fullness, which initiates activity in low-threshold mechanoceptive Aδ-fiber 
afferents during filling, and these afferents also convey the magnitude of detrusor 
contractions during the emptying phase [5]. Afferents are activated by both low (non-
nociceptive) and high (nociceptive) intravesical pressures. The efferent arm of neural control 
in micturition involves twin autonomic branches, namely the sympathetic branch, for 
controlling the bladder filling and parasympathetic branch for emptying. Increased firing in 
mechanoceptive afferents from bladder distension during filling phase reverses the pattern of 
efferent outflow through firing in the sacral parasympathetic pathways and completes 
inhibition of sympathetic and somatic pathways. Therefore, the relay of afferent input from 
the bladder to the neural circuitry in the brain stem, in particular, the periaqueductal gray 
(PAG) and PMC is crucial to switch on the periodic transformation of the lower urinary tract 
from the mode of bladder filling to emptying [6–8].
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Many neurotransmitters including acetylcholine, nor-epinephrine, dopamine, serotonin, 
excitatory and inhibitory amino acids, adenosine triphosphate, nitric oxide and 
neuropeptides are involved in the control of micturition [3]. Acetylcholine is the primary 
neurotransmitter effecting bladder emptying through its action on the muscarinic receptors 
on detrusor muscle [5], and the storage phase is mediated by norepinephrine released from 
sympathetic nerve terminals. Muscarinic receptors are classified based on molecular and 
pharmacological criteria into five subtypes (M1–M5), and detrusor muscle, like other forms 
of smooth muscle, exhibits a heterogeneous distribution of these receptor subtypes [9].
Complete voiding is initiated upon cessation of sympathetic and somatic inputs to the 
detrusor and sphincter, which causes sphincters to relax and the bladder neck to assume the 
shape of funnel, and the concomitant increased parasympathetic activity [9] causes 
generation of pressure for overcoming resistance generated by the collapsed urethra. 
Reversal in efferent outflow in both sympathetic and somatic innervation to the urethra and 
sphincter causes a reflex relaxation followed in a few seconds by parasympathetic-nerve-
mediated detrusor contraction. Nitric oxide released from the parasympathetic nerve 
terminals in the urethra also cause relaxation of urethral smooth muscle during voiding. As a 
result, the pressure inside the bladder rises and the urethral pressure falls, which is a 
prerequisite for the urine expulsion. Efficient voiding is also dependent on the activity of 
urethral afferents responding to urine flow. Activity in urethral afferents potentiates detrusor 
contraction through a feed-forward mechanism. Signal from urethral afferent is fed back to 
the motor system at several levels of control between the end organ and cortical brain 
function [10].
Current understanding of UAB pathophysiology
The prevalence of UAB is higher in the aged population and in the absence of other 
explanations some older adults are diagnosed with idiopathic UAB [11]. Nevertheless, 
advanced age does not by itself lead to clinically significant UAB. However, the potential 
contributions made by aging to this condition become apparent when UAB is viewed in the 
context of its multifactorial etiology with a role for both lower urinary tract and non-
genitourinary factors in its pathogenesis [2, 11]. As is common for many other multifactorial 
conditions and syndromes that commonly impact the health of older adults, a variety of 
predisposing and precipitating factors may jointly contribute [12]. Examples of risk factors 
that may alone or in conjunction with other considerations lead to UAB include bladder 
outlet obstruction; diabetes mellitus contributing to myogenic UAB; Parkinson’s disease 
with neurogenic UAB; multiple sclerosis; injury to the spinal cord and cauda equina (e.g., 
herniated disk, pelvic fractures); infectious neurological problems (e.g., AIDS, herpes zoster 
infection); plus pelvic surgery and radical prostatectomy, which can lead to iatrogenic UAB. 
Moreover, medications such as neuroleptics, calcium channel antagonists, and α-receptor 
agonists may also occasionally precipitate UAB in individuals who have presumably been 
rendered more vulnerable as a result of predisposing risk factors.
From a mechanistic point of view, the observation that advanced age is associated with an 
increased risk of UAB could be attributed to the existence of multiple morbidity, combined 
with a variety of biological changes, which likely to be relevant to UAB and which have 
Tyagi et al. Page 3









been linked to aging and/or common late life disease conditions. Among Americans 65 
years and older, more than one-half have been diagnosed with three or more chronic 
conditions [13]. Common chronic conditions such as diabetes mellitus are known to 
predispose individuals to UAB, while animal studies discussed below indicate that chronic 
ischemia commonly seen in the context of atherosclerosis and microvascular disease [14], a 
profound lack of estrogen seen in some postmenopausal women [15–18] or biological 
processes, which are intrinsic to aging [17, 19] could also potentially contribute to UAB by 
favoring the development of degenerative or biochemical changes involving key 
components of the detrusor muscle, its contractile machinery or its innervation. For 
example, there is a striking paucity of studies that would permit an examination of the 
relationship between menopause or estrogen status and UAB or DU. At the same time, 
studies using mature or aged animal models have shown that prolonged consequences of 
bilateral ovariectomy include relevant consequences such as axonal [18] and myocyte [18] 
degeneration as seen in older adults with UAB [20]; depletion of caveolae [17] with 
potential implications for age-associated changes in calcium signaling [19, 21] and declines 
in key proteins involved in smooth muscle contractility [16].
Three main hypotheses have been proposed for the mechanisms underlying UAB: 
neurogenic, myogenic and integrative. The neurogenic hypothesis focuses on defect in either 
afferent innervation or in its integrative control at spinal and supraspinal centers, which 
leads to poor efferent outflow. Myogenic hypothesis focuses on the periphery, in which the 
ability of the detrusor to contract efficiently is compromised by defect in the muscle itself.
Given the importance of an intact afferent system to voiding function, UAB may arise when 
the levels of afferent activity are disproportionately low for any given degree of bladder 
distention [22, 23]. There can be age-dependent loss of bladder volume sensitivity due to 
changes in neurotransmitter release from the urothelium as well as in the sensitivity and 
coupling of the suburothelial interstitial cell-afferent network. Afferents in the bladder and 
urethra can be damaged, for example, through an effect of aging or ischemia [24]. Urethral 
afferent dysfunction as a late consequence of diabetes [25] can also reduce or prematurely 
end the micturition reflex, leading to loss of voiding efficiency, as seen in diabetic 
cystopathy.
The myogenic hypothesis suggests that UAB results from changes within the bladder 
smooth muscle that lead to reduced excitability and loss of intrinsic muscle contractility in 
the bladder driving spontaneous contraction. Ultrastructural studies have revealed 
characteristic changes associated with UAB [26], which could potentially hinder efficient 
contraction of the detrusor muscle. Tenets of Laplace’s law dictate that rise in bladder 
capacity due to urine retention will by itself hinder generation of high enough intravesical 
pressure. Individuals with UAB may experience a greater decline in detrusor contractility 
than people with normal aging. When the disproportionate decline of detrusor contractility 
in affected individuals is not compensated by increase in release of neurotransmitters, then it 
can lead to UAB.
Autonomous detrusor activity detected during bladder filling [27] facilitates the generation 
of bladder sensation, and absence of spontaneous contractions can hinder the initiation of 
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afferent signals, which can lead to neurogenic UAB/DU from the impaired afferent arm. It 
can be difficult to isolate a neurogenic or myogenic component in patients with mixed UAB. 
In such cases, decreased detrusor contractility will lead to reduced autonomous activity of 
the bladder, which then can reduce the afferent return from the bladder.
The integrative hypothesis proposes that complex interactions among smooth muscle, 
connective tissue, urothelium and supportive structures with peripheral nerves contribute to 
normal generation of localized spontaneous activity that is observed as localized 
contractions and stretches (micromotions) in the human bladder [28]. These findings have 
led to the suggestion that the detrusor muscle is functionally modular in arrangement.
Ultrastructural features
The myogenic hypothesis suggests that UAB results from changes within the bladder 
smooth muscle that lead to reduced excitability and loss of intrinsic muscle contractility in 
the bladder driving spontaneous contraction. Ultrastructural studies have revealed 
characteristic changes associated with UAB [20, 29], which could potentially hinder 
efficient contraction of the detrusor muscle. There is also evidence in ultrastructural studies 
that degeneration of the detrusor muscle cell and disruption in normal detrusor fascicular 
architecture may contribute to poorer outcomes after TURP with respect to persistent 
urinary retention and raised post-void residual urine.
Importance of animal models
Until recently, clinical research in the field of lower urinary tract dysfunctions was limited to 
cystometry or molecular and cellular research using biopsy material from willing patients. 
However, recent advances in diagnostic and functional imaging have allowed brain mapping 
to study brain responses during bladder filling and emptying of subjects [30]. Since direct 
human experimentation on UAB subjects is not possible for ethical reasons, hypotheses 
stated for UAB will require alternatives to test the derived predictions. Animal models can 
be used to generate novel directions of research and corroborate findings obtained in case 
studies or other methods.
Animals that share similar integrative physiology of the lower urinary tract and the neural 
control of micturition as humans provide a suitable tool to dissect the underlying 
mechanisms in clinical features of UAB. Animal models can be used to reproduce some or 
all of the facets of UAB seen clinically as a consequence of neurogenic or myogenic 
dysfunction to help identify suitable interventions. Animal models provide suitable 
platforms of “intact” biological systems for assessing results from simpler in vitro research. 
The clinical context of animal studies can help build a confidence in a new treatment 
approach before clinical testing.
Development of an animal model for UAB is hindered by the lack of a surrogate that 
predicts treatment outcome. The clinically meaningful endpoints are changes in urinary 
frequency and voided volumes. Animal models can be classified as exploratory, explanatory 
or predictive—depending on the type of information that they are designed to yield. 
Exploratory models are used to study physiological processes and pathological mechanisms 
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in UAB in order to generate novel ideas and theories about physiological function. 
Explanatory models are developed and applied in an attempt to improve our understanding 
of the importance and relevance of findings generated by other models. Predictive or 
preclinical models are those used to discover and quantify the impact of novel treatments 
and therapeutic agents and to assess their toxicity to the living organism.
Animal models of UAB
Epidemiology has guided most of the animal research on UAB so far. UAB is mostly seen in 
aged patients [31]; therefore, aged animals are preferred as exploratory UAB models. All 
patients with neurological disorders experience some form of lower urinary tract dysfunction
—no matter how mild their disease is—they inevitably develop a bladder-related problem. 
This has led to the development of a large range of neurological models. The inciting event 
of neurological defect such as cerebrovascular event or a spinal cord injury can be 
recapitulated to induce equivalent changes in explanatory animal models. Considering the 
association of UAB with diabetes, chronic effects of chemically induced diabetes on bladder 
function have been studied as a UAB model. Unfortunately, this approach to modeling is 
complicated by the fact that the bladder has a limited repertoire of responses to injury, and 
thus, differing etiological factors may produce a similar picture in affected individuals. 
Moreover, animal modeling, which focuses on addressing a single etiological factor at a 
time, may not suffice when seeking to define the pathophysiology of a highly complex 
multifactorial condition. With these considerations in mind, future animal model studies 
may need to explore interactions between more than one predisposing or provocative risk 
factors in their ability to contribute to UAB or relevant proxy measures.
Aged rodent models
Animal models of idiopathic UAB are difficult, so phenotypic models are used in which an 
animal expresses cystometric or voiding features resembling those seen in UAB patients. 
Aged mouse [22, 32] or rat models reproduce some of the UAB features, with age-
dependent loss of bladder volume sensitivity manifesting as increased inter-contractile 
interval. Cystometry of young and old mice shows that detrusor contractility is preserved, 
but the response to rise in bladder volume is diminished, which is evident from an increase 
in intercontractile interval at 26 months. Similar findings were observed in aged rats with 
increased volume and pressure thresholds for voiding [33]. Age-dependent loss of bladder 
volume sensitivity in aged rats may be explained by the decreased response to intravesical 
capsaicin, which is suggestive of reduced C-fiber afferent activity in aged rat [33]. 
Intravesical capsaicin is expected to increase detrusor contractility because of neurokinins 
released from afferent nerves following activation of transient receptor potential (TRP) 
channels. Aged rats also exhibit a reduction in the maximal bladder pressure generated 
during pelvic nerve stimulation [34–36]. Staining for calcitoningene-related peptide (CGRP) 
and substance P in lumbosacral dorsal root ganglion DRG neurons [37] and density of 
pituitary adenylate cyclase-activating peptide (PACAP) innervation of the bladder base are 
also decreased in aged rats [38].
In addition, aged male rats exhibited urethral dysfunction and impairment of the 
urethrovesical coordination, which further corroborates that complete bladder emptying 
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relies on reciprocal contraction and relaxation of smooth muscle in the bladder and urethra, 
respectively [39–41]. Decrease in resting urethral pressure at voiding threshold and the 
occurrence of a significant delay in urethral relaxation that leads to increased PVR was 
observed in aged male rats. The maximal responses to carbachol in the bladder body and to 
phenylephrine and carbachol in the urethra were also observed to be diminished in the aged 
male rat bladder. Significant decreases in the amplitude of neurogenic contractions were 
associated with fibrosis but without accompanying a decrease in nerve density in the bladder 
neck. Thus, these findings from aged rats implicate impairment of both afferent and efferent 
transmission results in incomplete voiding. There is also an upregulation of purinergic 
receptors in the urothelium and bladder nerve bundles compared to control rats, perhaps 
corresponding to the increased non-adrenergic and non-cholinergic (NANC) innervation 
seen in aging humans. Upregulation of β-adrenoceptors [42] is also reported in aged rat 
bladder [41], and the pathological relevance of altered receptor expression in UAB will be 
interesting to investigate. Recent findings also suggest that the cellular basis of age-related 
cognitive decline manifesting in cAMP signaling and KCNQ channels share some parallels 
with age-related decline in bladder contractility.
Peripheral versus central models
Animal models of UAB can be broadly divided into peripheral and central models based on 
the predominant site of the deficit. Peripheral models are those resulting from direct damage 
to the bladder, its peripheral innervation or blood supply, whereas central models are 
developed following injuries to the spinal cord, brainstem or higher centers.
Diabetic bladder dysfunction (DBD) models
DBD describes storage and voiding problems, as well as other less clinically defined 
phenotypes, such as decreased sensation and increased bladder capacity in both type I and 
type II diabetes mellitus (DM) [43–47]. Systemic administration of streptozotocin is used to 
induce DM in rats, which is confirmed by increases in blood glucose and urine production. 
Animals show time-dependent changes in cystometry with initial compensated changes 
similar to detrusor overactivity. The decompensated stage at 12 weeks shows features of 
UAB that are the result of long-term hyperglycemia-related oxidative stress and polyuria. 
The STZ-induced DBD is associated with increased bladder weight and residual urine, 
which indicates the incomplete bladder emptying. Streptozotocin-induced DBD affects Aδ-
fiber afferent-dependent conscious voiding, which was evaluated in metabolic cage 
measurements and awake cystometry [43–47]. The impairment of C-fiber-mediated bladder 
nociceptive responses in the DBD bladder was revealed by reduced sensitivity of C-fiber-
afferent pathways to nociceptive stimuli during 0.25 % acetic acid cystometry of rats with 
DBD under urethane anesthesia [46].
Genetically engineered mouse models have also been developed that display salient features 
of DBD relevant to UAB. Liver-specific deletion of insulin receptor substrate 1 (IRS1) and 
IRS2 leads to hyperglycemia by 5 weeks of life [48, 49] and development of DBD that 
models pathologic changes in humans with type II DM [50] Importantly, the IRS1:IRS2 
double-knockout model displays bladder overactivity in young mice, but bladder 
underactivity in older animals. Detrusor underactivity was characterized by decreased force 
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generation in muscle strips from older diabetic mice compared with age-matched controls in 
response to electrical field stimulation, carbachol and KCl-mediated depolarization [25].
Diabetes-induced urethral dysfunction
Urethral dysfunction is believed to cause changes in voiding behavior of aged male rats [39–
41], which results in decreased resting urethral pressure at voiding threshold and the 
occurrence of a significant delay in urethral relaxation. Therefore, impaired urethral 
relaxation can also prolong the bladder emptying during voiding phase. Urethral dysfunction 
is also a consequence of diabetes, which we have studied (Fig. 1) [51, 52] as well as other 
labs [25, 53]. Nitric oxide-mediated relaxation of the urethra is considered to be impaired in 
diabetes. Other studies have reported damage to urethral afferents, which reduces or 
prematurely ends the micturition reflex, leading to loss of voiding efficiency, as in diabetic 
cystopathy. DBD is also associated with altered receptor expression [54] and changes in 
NANC transmission [55, 56].
Ischemia and hyperlipidemia
Epidemiological studies have suggested bladder ischemia and metabolic syndrome as likely 
etiological factors of UAB. The underlying pathological mechanisms have not been clearly 
defined, but current evidence suggests that there is likely to be both a vascular and 
neurogenic component. Chronic bladder ischemia [57] secondary to atherosclerosis assists 
the progression of OAB into UAB. Cystometry of myocardial infarction-prone Watanabe 
heritable hyperlipidemic (WHHLMI) rabbits show significantly shorter micturition intervals, 
smaller voided volume with non-voiding contractions and lower micturition pressure [58], 
as compared to control animals. The carbachol and electrical field stimulation-induced 
contractions of WHHLMI detrusor strips were also significantly decreased. This animal 
model would serve well to screen for drugs that seek to improve detrusor contractility.
Neurological models of UAB
Functional imaging has provided many insights into the age-related decrease in responses 
within the brain regions involved in interpretation of afferent inputs from the bladder. 
Dysfunction of the central control of the voiding reflex can lead to UAB by impacting upon 
key processes in perception, integration, and outflow. Considering that voluntary voiding is 
a learned phenomenon, age-related decline of dopamine binding has been reported in brain 
areas involved in cognition [59]. In fact, brain areas involved in cognition overlap with areas 
involved in processing afferent input from the bladder, which implicate the dopamine role in 
central transmission as key for UAB.
The central control of micturition is highly complex, and the voiding disturbance that 
develops will depend on the location and extent of the neurological injury. A number of 
central nervous system disorders cause voiding dysfunction in humans, including 
cerebrovascular events, dementia, Parkinson’s disease, multiple sclerosis and stroke. The 
coordination between the detrusor smooth muscle and the sphincter mechanism of the 
bladder occurs in the pontine region of the brainstem. On the other hand, patients with spinal 
cord injuries will present with a variety of lower urinary tract signs and symptoms 
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depending on the level of injury, and whether it is partial or complete. Neurological models 
improve our understanding of the complex pathways controlling micturition.
Parkinson’ disease
PD is a chronic and progressive degenerative disease of the brain characterized by selective 
destruction of striatal dopaminergic neurons that pass from the substantia nigra pars 
compacta to the putamen. PD can be induced in monkeys by administering the neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is selective for dopaminergic 
neurons in the substantia nigra. In MPTP-treated monkeys, cystometry showed that injection 
of a dopamine D1 receptor agonist significantly increases the bladder volume and pressure 
thresholds for inducing the micturition reflex, with no corresponding effect seen in normal 
monkeys [60, 61].
Lumbar canal stenosis (LCS) for UAB
LCS induces mechanical compression of the cauda equina by insertion of silicon rubber 
pieces into the L6 epidural space in female rats [62]. The mechanical compression causes 
degeneration of both afferent and efferent spinal nerves involved in voiding. The animal 
model exhibits both decreased voiding efficiency and reduced detrusor contractility.
Ventral avulsion model for UAB
Trauma to the thoracolumbar spine commonly results in injuries to the cauda equina and the 
lumbosacral portion of the spinal cord. A unilateral L5-S2 ventral root avulsion (VRA) 
injury in rats mimics a partial lesion to the cauda equina and conus medullaris [63]. Detailed 
cystometrogram studies found that a markedly reduced voiding efficiency was noted at 12 
weeks after the VRA injury with decreased maximum amplitude to indicate reduced 
contractile stimuli. Concurrent external urethral sphincter (EUS) electromyography 
demonstrated shortened burst and prolonged silent periods associated with the elimination 
phase [63]. The animal model demonstrated that a 5HT1A receptor agonist, 8-hydroxy-2-
(di-n-propylamino)-tetralin (8-OH-DPAT), administered intravenously, elicited the 
supraspinal micturition reflex during cystometry.
Pelvic nerve injury for iatrogenic UAB
Latrogenic UAB is often associated with pelvic nerve injury induced by pelvic organ 
surgery. The animal model was developed for UAB by performing a bilateral pelvic nerve 
crush in adult female rats with a straight micro-mosquito clamp as illustrated in Fig. 2. The 
clamp was used to crush each pelvic nerve for a total of 30 s. The crush was performed 
proximal to each pelvic nerve’s entry into the major pelvic ganglion. Pelvic nerve crush 
injury caused significant increases in bladder capacity in cystometry performed 1 week after 
nerve injury as shown in Fig. 3. The model shows increased PVR and decreases in 
maximum voiding pressure and voiding efficiency in cystometry. Animals with pelvic nerve 
injury may also serve as a model of neurogenic UAB as afferent and efferent nerve 
dysfunction is known to be one of major causes of UAB, as discussed above.
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Advances in genetic engineering techniques have led to an increasing use of genetically 
modified organisms for research. The mouse is most commonly employed, given that its 
genome is completely sequenced, is easy to maintain and has a relatively short generation 
span. Several transgenic mouse models have demonstrated that molecular alterations in the 
urothelium, peripheral innervation and smooth muscle leads to significant changes in 
voiding function [64]. However, the full power of this technology could not be harnessed 
until the recent description of experimental approaches permitting the continuous 
comprehensive urodynamic assessment involving concurrent measurements of pressure, 
volume and flow in mice [22, 65].
Prostaglandin receptor knockout mouse
Prostaglandins are produced by the constitutively expressed cyclooxygenase-(COX) 1 
enzyme, and an inducible isozyme, COX-2 in urothelium [66–69]. Prostaglandin E2 (PGE2) 
produced by this enzyme is decreased in the urine of UAB patients [70]. PGE2 mediates its 
effects by activating the EP family (EP1–EP4 isoforms) of G-protein-coupled receptors. 
PGE2 have a physiological role as it is produced by detrusor muscle in response to stretch. 
Mouse knockout models of the EP3 receptor showed enlarged bladder capacity [71], which 
could be used to screen drugs and test new hypothesis for UAB. Since EP3 knockout mice 
do not exhibit bladder overactivity after instillation of an EP3 receptor agonist, changes in 
peripheral afferent sensitivity in this model cannot be ruled out.
Purinergic receptor knockout mouse
ATP is released from human and animal urothelium in response to mechanical stretch. 
Prostaglandins were shown to be involved in the stretch evoked ATP release from the 
urothelium [72]. ATP acts as a sensory neurotransmitter by binding to purinergic receptors 
(P2X) on suburothelial afferent nerve endings. P2X3 receptor knockout mice appear to have 
reduced bladder sensation, with reduced urinary frequency and larger voided volumes [73–
76].
Models of myogenic UAB
Decreased detrusor contractility in UAB can result from a lack of contractile stimulus 
(acetylcholine and ATP) [77] and/or a lack of tissue responsiveness due to irreversible 
changes in the bladder wall described as sarcopenia (loss of muscle tissue, increased 
collagen deposition) [26, 78]. Several factors may contribute to altered excitation–
contraction coupling mechanisms including changes in the properties and density of calcium 
[79] and potassium channels, gap junctions and receptors in detrusor smooth muscles of 
aged and UAB patients.
Bladder outlet obstruction BOO
Effects similar to BOO in humans are relatively straightforward to replicate in animals. This 
has been achieved in a variety of animal species including the pig, rat, guinea pig and rabbit 
by inducing partial obstruction of the urethra using some form of ligature that either 
occludes/stenoses the urethra immediately or does so gradually as the animal grows [80]. 
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Partial BOO was induced in adult female rats by ligating the proximal urethra over a 1-mm 
angiocatheter for 2 weeks to 6 months. Prolonged BOO caused a decrease in electric field 
stimulation (EFS, 2.5–40 Hz)-induced acetylcholine release and the number of nerves in the 
rat urinary bladder, which might contribute to detrusor underactivity (UAB) in BOO. The 
amount of acetylcholine was measured in the dialysate fraction obtained from a 
microdialysis probe inserted into the muscle strips during EFS. The reduced density of 
acetylcholinesterase-positive nerves in obstructed bladders without overt neurological 
disease can also cause insufficient efferent activation to occur.
Limitations of animal research
An ideal model would be one which replicates the symptoms, etiology and natural history of 
clinical UAB. Most of the animal models discussed here do not essentially mimic UAB, but 
bear enough similarities to make them relevant for a limited number of aspects of the human 
condition. It is inconceivable that any single animal model will replicate all the voiding 
features and consequences observed in UAB patients. Animal models need to be viewed as 
research tools to answer a particular experimental hypothesis rather than replicas of clinical 
UAB.
Studies using rodents and small laboratory animals are relatively simpler to perform and 
maintain than studies done using larger animals. Research done with small mammals is less 
expensive, more accessible and less time consuming to carry out. Irrespective of the animal 
species and model used, it is useful to determine the clinical relevance of the findings within 
the limitations of the model. Rodents can adapt to surgically induced alterations through 
neural plasticity and cellular adaptations. Therefore, experimental findings may represent 
compensatory changes or collateral effects rather than having pathophysiological relevance 
for UAB. It may also be that the changes seen are epiphenomena, being totally unrelated to 
the underlying pathological process and occurring by coincidence.
Furthermore, there are significant differences in the composition of the urinary bladder wall 
between small and large animal bladders, which can introduce variability in urodynamic 
features. The location of postganglionic parasympathetic cell bodies innervating the rat 
bladder is entirely in the pelvic ganglia, whereas a substantial proportion of these cell bodies 
are located in the bladder wall of humans and other animal species [81]. Therefore, the 
outcomes following partial BOO differs between species [82, 83]. Unlike rats, long-term 
untreated BOO does not appear to result in significant clinical decompensation of detrusor 
function in most men. Treatments targeted at reducing urethral resistance improved UAB 
symptoms [84].
The structural and functional differences discussed above are but a few examples of the 
interspecies variability, which are relevant to animal modeling of UAB and prevent 
erroneous conclusions [84]. It is important that these aspects are taken into account for 
identifying experimental findings that constitute general principles and are predictive of 
clinical efficacy from those that are unique to a model. The interspecies variability lends 
different strengths and weaknesses to each model and makes them suitable for studying 
different aspects of UAB. Regardless of the type of model used, careful validation of both 
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the model itself and the results that it generates ensure that any findings are correctly 
extrapolated from animals to humans. The validation required will depend on how closely 
the model reproduces a disease or condition.
Conclusions
Research into the pathogenesis of detrusor underactivity and underactive bladder is 
hampered by the fact that it is currently an urodynamic-based diagnosis and does not 
appreciate the sensory afferent’s or the central nervous system’s role in UAB etiology. 
Despite the difficulties associated with animal modeling, there is no substitute for their use 
as tools to advance understanding and develop medical interventions for UAB. The various 
models that have been used to date have different strengths and weaknesses, and the findings 
should ideally be reproduced in more than one mammalian species before extrapolating data 
to human subjects.
Acknowledgments
Funding for this conference was made possible (in part) by 1R13AG047010 from the National Institute on Aging. 
The views expressed in written conference materials or publications and by speakers and moderators do not 
necessarily reflect the official policies of the NIH; nor does mention by trade names, commercial practices, or 
organizations imply endorsement by the U.S. Government.
References
1. Jeong SJ, Kim HJ, Lee YJ, Lee JK, Lee BK, Choo YM, Oh JJ, Lee SC, Jeong CW, Yoon CY, Hong 
SK, Byun SS, Lee SE. Prevalence and clinical features of detrusor underactivity among elderly with 
lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012; 53(5):
342–348.10.4111/kju.2012.53.5.342 [PubMed: 22670194] 
2. Miyazato M, Yoshimura N, Chancellor MB. The other bladder syndrome: underactive bladder. Rev 
Urol. 2013; 15(1):11–22. [PubMed: 23671401] 
3. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol. 
2006; 147(Suppl 2):S25–S40. [PubMed: 16465182] 
4. Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional 
Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J 
Urol. 2009; 35(1):76–83. [PubMed: 19254402] 
5. Tyagi P, Chancellor MB, Li Z, De Groat WC, Yoshimura N, Fraser MO, Huang L. Urodynamic and 
immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel 
and liposomes. J Urol. 2004; 171(1):483–489.10.1097/01.ju.0000102360.11785.d7 [PubMed: 
14665960] 
6. de Groat WC. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 1993; 20(3):
383–401. [PubMed: 8351765] 
7. de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997; 50(6A Suppl):36–52. 
(discussion 53–36). [PubMed: 9426749] 
8. de Groat WC, Araki I, Vizzard MA, Yoshiyama M, Yoshimura N, Sugaya K, Tai C, Roppolo JR. 
Developmental and injury induced plasticity in the micturition reflex pathway. Behav Brain Res. 
1998; 92(2):127–140. [PubMed: 9638955] 
9. Tyagi S, Tyagi P, Vanle S, Yoshimura N, Chancellor MB, de Miguel F. Qualitative and quantitative 
expression profile of muscarinic receptors in human urothelium and detrusor. J Urol. 2006; 176(4 Pt 
1):1673–1678.10.1016/j.juro.2006.06.088 [PubMed: 16952712] 
10. de Groat WC, Fraser MO, Yoshiyama M, Smerin S, Tai C, Chancellor MB, Yoshimura N, 
Roppolo JR. Neural control of the urethra. Scand J Urol Nephrol Suppl. 2001; 207:35–43. 
(discussion 106–125). [PubMed: 11409613] 
Tyagi et al. Page 12









11. Taylor JA 3rd, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an 
underdiagnosed geriatric condition. J Am Geriatr Soc. 2006; 54(12):1920–1932.10.1111/j.
1532-5415.2006.00917.x [PubMed: 17198500] 
12. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and 
policy implications of a core geriatric concept. J Am Geriatr Soc. 2007; 55(5):780–791.10.1111/j.
1532-5415.2007.01156.x [PubMed: 17493201] 
13. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition–
multimorbidity. J Am Med Assoc. 2012; 307(23):2493–2494.10.1001/jama.2012.5265
14. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of chronic hyperlipidemia on 
bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) 
rabbits. Neurourol Urodyn. 2010; 29(7):1350–1354.10.1002/nau.20843 [PubMed: 20127840] 
15. Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting 
with lower urinary tract symptoms. Urol. 2007; 69(3):436–440.10.1016/j.urology.2006.11.019 
[PubMed: 17382138] 
16. Sanchez-Ortiz RF, Wang Z, Menon C, DiSanto ME, Wein AJ, Chacko S. Estrogen modulates the 
expression of myosin heavy chain in detrusor smooth muscle. Am J Physiol Cell Physiol. 2001; 
280(3):C433–C440. [PubMed: 11171561] 
17. Zhu Q, Resnick NM, Elbadawi A, Kuchel GA. Estrogen and postnatal maturation increase 
caveolar number and caveolin-1 protein in bladder smooth muscle cells. J Urol. 2004; 171(1):467–
471.10.1097/01.ju.0000099480.18735.49 [PubMed: 14665957] 
18. Zhu Q, Ritchie J, Marouf N, Dion SB, Resnick NM, Elbadawi A, Kuchel GA. Role of ovarian 
hormones in the pathogenesis of impaired detrusor contractility: evidence in ovariectomized 
rodents. J Urol. 2001; 166(3):1136–1141. [PubMed: 11490312] 
19. Lowalekar SK, Cristofaro V, Radisavljevic ZM, Yalla SV, Sullivan MP. Loss of bladder smooth 
muscle caveolae in the aging bladder. Neurourol Urodyn. 2012; 31(4):586–592.10.1002/nau.21217 
[PubMed: 22374691] 
20. Haferkamp A, Dorsam J, Resnick NM, Yalla SV, Elbadawi A. Structural basis of neurogenic 
bladder dysfunction. III. Intrinsic detrusor innervation. J Urol. 2003; 169(2):555–
562.10.1097/01.ju.0000045753.02559.37 [PubMed: 12544306] 
21. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging 
detrusor: normal versus impaired contractility. J Urol. 1993; 150(5 Pt 2):1657–1667. [PubMed: 
8411454] 
22. Smith PP, DeAngelis A, Kuchel GA. Detrusor expulsive strength is preserved, but responsiveness 
to bladder filling and urinary sensitivity is diminished in the aging mouse. Am J Physiol Regul 
Integr Comp Physiol. 2012; 302(5):R577–R586.10.1152/ajpregu.00508.2011 [PubMed: 
22204955] 
23. Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol 
Urodyn. 2010; 29(3):408–412.10.1002/nau.20765 [PubMed: 19760756] 
24. Azadzoi KM, Radisavljevic ZM, Siroky MB. Effects of ischemia on tachykinin-containing nerves 
and neurokinin receptors in the rabbit bladder. Urology. 2008; 71(5):979–983.10.1016/j.urology.
2007.11.012 [PubMed: 18314167] 
25. Yang Z, Dolber PC, Fraser MO. Differential vulnerabilities of urethral afferents in diabetes and 
discovery of a novel urethra-to-urethra reflex. Am J Physiol Renal Physiol. 2010; 298(1):F118–
F124.10.1152/ajprenal.00281.2009 [PubMed: 19864303] 
26. Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ. A prospective controlled 
quantitative study of ultrastructural changes in the underactive detrusor. J Urol. 2003; 169(4):
1374–1378.10.1097/01.ju.0000055781.07630.aa [PubMed: 12629365] 
27. Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010; 29(1):
97–106.10.1002/nau.20784 [PubMed: 20025035] 
28. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human 
bladder and in urinary urgency. BJU Int. 2005; 95(7):1002–1005.10.1111/j.1464-410X.
2005.05455.x [PubMed: 15839921] 
Tyagi et al. Page 13









29. Blatt AH, Brammah S, Tse V, Chan L. Transurethral prostate resection in patients with 
hypocontractile detrusor—what is the predictive value of ultrastructural detrusor changes? J Urol. 
2012; 188(6):2294–2299.10.1016/j.juro.2012.08.010 [PubMed: 23083643] 
30. Griffiths DJ. Use of functional imaging to monitor central control of voiding in humans. Handb 
Exp Pharmacol. 2011; 202:81–97.10.1007/978-3-642-16499-6_5 [PubMed: 21290223] 
31. Zimmern P, Litman HJ, Nager CW, Lemack GE, Richter HE, Sirls L, Kraus SR, Sutkin G, Mueller 
ER. Effect of aging on storage and voiding function in women with stress-predominant urinary 
incontinence. J Urol. 201410.1016/j.juro.2014.01.092
32. Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT. Using caveolin-1 knockout mouse to 
study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. 
Urology. 2007; 69(2):407–411.10.1016/j.urology.2006.12.018 [PubMed: 17320698] 
33. Chai TC, Andersson KE, Tuttle JB, Steers WD. Altered neural control of micturition in the aged 
F344 rat. Urol Res. 2000; 28(5):348–354. [PubMed: 11127716] 
34. Hotta H, Morrison JF, Sato A, Uchida S. The effects of aging on the rat bladder and its innervation. 
Jpn J Physiol. 1995; 45(5):823–836. [PubMed: 8713179] 
35. Hotta H, Uchida S. Aging of the autonomic nervous system and possible improvements in 
autonomic activity using somatic afferent stimulation. Geriatr Gerontol Int. 2010; 10(Suppl 
1):S127–S136.10.1111/j.1447-0594.2010.00592.x [PubMed: 20590828] 
36. Mohammed HA, Santer RM. Distribution and changes with age of calcitonin gene-related peptide- 
and substance P-immunoreactive nerves of the rat urinary bladder and lumbosacral sensory 
neurons. Eur J Morphol. 2002; 40(5):293–301. [PubMed: 15101445] 
37. Mohammed H, Hannibal J, Fahrenkrug J, Santer R. Distribution and regional variation of pituitary 
adenylate cyclase activating polypeptide and other neuropeptides in the rat urinary bladder and 
ureter: effects of age. Urol Res. 2002; 30(4):248–255.10.1007/s00240-002-0261-6 [PubMed: 
12202943] 
38. Lluel P, Deplanne V, Heudes D, Bruneval P, Palea S. Age-related changes in urethrovesical 
coordination in male rats: relationship with bladder instability? Am J Physiol Regul Integr Comp 
Physiol. 2003; 284(5):R1287–R1295.10.1152/ajpregu.00499.2001 [PubMed: 12505867] 
39. Lluel P, Palea S, Barras M, Grandadam F, Heudes D, Bruneval P, Corman B, Martin DJ. 
Functional and morphological modifications of the urinary bladder in aging female rats. Am J 
Physiol Regul Integr Comp Physiol. 2000; 278(4):R964–R972. [PubMed: 10749785] 
40. Lluel P, Palea S, Ribiere P, Barras M, Teillet L, Corman B. Increased adrenergic contractility and 
decreased mRNA expression of NOS III in aging rat urinary bladders. Fundam Clin Pharmacol. 
2003; 17(5):633–641. [PubMed: 14703725] 
41. Iaina A, Serban I, Kapuler S, Gavendo S, Lindner A, Eliahou HE. Beta-adrenergic receptors in the 
urinary bladder of adult and developing rats. Isr J Med Sci. 1988; 24(4–5):237–240. [PubMed: 
2897955] 
42. Goins WF, Yoshimura N, Phelan MW, Yokoyama T, Fraser MO, Ozawa H, Bennett NJ, de Groat 
WC, Glorioso JC, Chancellor MB. Herpes simplex virus mediated nerve growth factor expression 
in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol. 2001; 
165(5):1748–1754. [PubMed: 11342969] 
43. Gray MA, Wang CC, Sacks MS, Yoshimura N, Chancellor MB, Nagatomi J. Time-dependent 
alterations of select genes in streptozotocin-induced diabetic rat bladder. Urology. 2008; 71(6):
1214–1219.10.1016/j.urology.2007.11.054 [PubMed: 18279932] 
44. Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC, Yoshimura N. 
Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth 
factor in a rat model of diabetic cystopathy. Diabetes. 2004; 53(10):2723–2730. [PubMed: 
15448108] 
45. Sasaki K, Chancellor MB, Phelan MW, Yokoyama T, Fraser MO, Seki S, Kubo K, Kumon H, 
Groat WC, Yoshimura N. Diabetic cystopathy correlates with a long-term decrease in nerve 
growth factor levels in the bladder and lumbosacral dorsal root Ganglia. J Urol. 2002; 168(3):
1259–1264.10.1097/01.ju.0000023400.17372.3e [PubMed: 12187278] 
46. Sasaki K, Yoshimura N, Chancellor MB. Implications of diabetes mellitus in urology. Urol Clin 
North Am. 2003; 30(1):1–12. [PubMed: 12580554] 
Tyagi et al. Page 14









47. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. Inactivation of hepatic 
Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth 
regulation. Cell Metab. 2008; 8(1):65–76.10.1016/j.cmet.2008.06.006 [PubMed: 18590693] 
48. Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, Depinho RA, Puigserver P, White 
MF. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009; 
15(11):1307–1311.10.1038/nm.2049 [PubMed: 19838201] 
49. Wang Z, Cheng Z, Cristofaro V, Li J, Xiao X, Gomez P, Ge R, Gong E, Strle K, Sullivan MP, 
Adam RM, White MF, Olumi AF. Inhibition of TNF-alpha improves the bladder dysfunction that 
is associated with type 2 diabetes. Diabetes. 2012; 61(8):2134–2145.10.2337/db11-1763 [PubMed: 
22688336] 
50. Torimoto K, Fraser MO, Hirao Y, De Groat WC, Chancellor MB, Yoshimura N. Urethral 
dysfunction in diabetic rats. J Urol. 2004; 171(5):1959–1964.10.1097/01.ju.0000121283.92963.05 
[PubMed: 15076321] 
51. Torimoto K, Hirao Y, Matsuyoshi H, de Groat WC, Chancellor MB, Yoshimura N. alpha1-
Adrenergic mechanism in diabetic urethral dysfunction in rats. J Urol. 2005; 173(3):1027–
1032.10.1097/01.ju.0000146268.45662.36 [PubMed: 15711370] 
52. Christ GJ, Bushman W, Fraser MO. Impact of diabetes and obesity on the prostate and urethra: 
implications to improved bladder dysfunction understanding and treatment. J Urol. 2009; 182(6 
Suppl):S38–S44.10.1016/j.juro.2009.07.085 [PubMed: 19846131] 
53. Li Y, Sun Y, Zhang Z, Feng X, Meng H, Li S, Zhu Y, Chen S, Wang Y, Wang J, Zhang D, Jiang 
X, Li N, Shi B. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an 
experimental diabetic rat model. BJU Int. 2013; 112(2):E143–E150.10.1111/bju.12172 [PubMed: 
23795792] 
54. Bschleipfer T, Nandigama R, Moeller S, Illig C, Weidner W, Kummer W. Bladder outlet 
obstruction influences mRNA expression of cholinergic receptors on sensory neurons in mice. Life 
Sci. 2012; 91(21–22):1077–1081.10.1016/j.lfs.2012.05.007 [PubMed: 22634327] 
55. Philyppov IB, Paduraru ON, Andreev YA, Grishin EV, Shuba YM. Modulation of TRPV1-
dependent contractility of normal and diabetic bladder smooth muscle by analgesic toxins from sea 
anemone Heteractis crispa. Life Sci. 2012; 91(19–20):912–920.10.1016/j.lfs.2012.09.001 
[PubMed: 22982418] 
56. Fu LW, Longhurst JC. Role of 5-HT3 receptors in activation of abdominal sympathetic C fibre 
afferents during ischaemia in cats. J Physiol. 1998; 509(Pt 3):729–740. [PubMed: 9596795] 
57. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of chronic hyperlipidemia on 
bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) 
rabbits. Neurourol Urodyn. 2010; 29(7):1350–1354.10.1002/nau.20843 [PubMed: 20127840] 
58. MacDonald SW, Karlsson S, Rieckmann A, Nyberg L, Backman L. Aging-related increases in 
behavioral variability: relations to losses of dopamine D1 receptors. J Neurosci. 2012; 32(24):
8186–8191.10.1523/JNEUROSCI.5474-11.2012 [PubMed: 22699899] 
59. Kobayashi S, Muroyama A, Matsushima H, Yoshimura I, Mitsumoto Y. Oral administration of 
coenzyme Q(1)(0) reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in 
mice. Neurol Sci. 2012; 33(1):195–199.10.1007/s10072-011-0627-z [PubMed: 21598008] 
60. Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 
38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology. 1993; 32(4):315–321. [PubMed: 
8098860] 
61. Sekido N, Jyoraku A, Okada H, Wakamatsu D, Matsuya H, Nishiyama H. A novel animal model 
of underactive bladder: analysis of lower urinary tract function in a rat lumbar canal stenosis 
model. Neurourol Urodyn. 2012; 31(7):1190–1196.10.1002/nau.21255 [PubMed: 22473471] 
62. Chang HH, Havton LA. Serotonergic 5-HT(1A) receptor agonist (8-OH-DPAT) ameliorates 
impaired micturition reflexes in a chronic ventral root avulsion model of incomplete cauda equina/
conus medullaris injury. Exp Neurol. 2013; 239:210–217.10.1016/j.expneurol.2012.10.015 
[PubMed: 23099413] 
63. Schnegelsberg B, Sun TT, Cain G, Bhattacharya A, Nunn PA, Ford AP, Vizzard MA, Cockayne 
DA. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic 
Tyagi et al. Page 15









sensitivity, and changes in urinary bladder function. Am J Physiol Regul Integr Comp Physiol. 
2010; 298(3):R534–R547.10.1152/ajpregu.00367.2009 [PubMed: 20032263] 
64. Smith PP, Kuchel GA. Continuous uroflow cystometry in the urethane-anesthetized mouse. 
Neurourol Urodyn. 2010; 29(7):1344–1349.10.1002/nau.20850 [PubMed: 20127833] 
65. Rahnama’i MS, Biallosterski BT, de Wachter SG, Van Kerrebroeck PE, van Koeveringe GA. The 
distribution of the prostaglandin E receptor type 2 (EP2) in the detrusor of the guinea pig. 
Prostaglandins Other Lipid Mediat. 2012; 99(3–4):107–115.10.1016/j.prostaglandins.2012.08.005 
[PubMed: 22960431] 
66. Rahnama’i MS, de Wachter SG, van Koeveringe GA, van Kerrebroeck PE, de Vente J, Gillespie 
JI. The relationship between prostaglandin E receptor 1 and cyclooxygenase I expression in guinea 
pig bladder interstitial cells: proposition of a signal propagation system. J Urol. 2011; 185(1):315–
322.10.1016/j.juro.2010.09.005 [PubMed: 21075388] 
67. Rahnama’i MS, van Kerrebroeck PE, de Wachter SG, van Koeveringe GA. The role of prostanoids 
in urinary bladder physiology. Nat Rev Urol. 2012; 9(5):283–290.10.1038/nrurol.2012.33 
[PubMed: 22410675] 
68. Rahnama’i MS, van Koeveringe GA, Essers PB, de Wachter SG, de Vente J, van Kerrebroeck PE, 
Gillespie JI. Prostaglandin receptor EP1 and EP2 site in guinea pig bladder urothelium and lamina 
propria. J Urol. 2010; 183(3):1241–1247.10.1016/j.juro.2009.11.004 [PubMed: 20096878] 
69. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK. Changes of urinary nerve growth factor 
and prostaglandins in male patients with overactive bladder symptom. Int J Urol. 2005; 12(10):
875–880.10.1111/j.1442-2042.2005.01140.x [PubMed: 16323980] 
70. McCafferty GP, Misajet BA, Laping NJ, Edwards RM, Thorneloe KS. Enhanced bladder capacity 
and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice. Am 
J Physiol Renal Physiol. 2008; 295(2):F507–F514.10.1152/ajprenal.00054.2008 [PubMed: 
18508878] 
71. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O. Modulation of stretch evoked 
adenosine triphosphate release from bladder epithelium by prostaglandin E(2). J Urol. 2011; 
185(1):341–346.10.1016/j.juro.2010.09.042 [PubMed: 21075387] 
72. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, 
Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following 
intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005; 174(3):
977–982. discussion 982–973. 10.1097/01.ju.0000169481.42259.54 [PubMed: 16094018] 
73. Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, Ruan HZ, Ma B, Yip P, 
Nunn P, McMahon SB, Burnstock G, Ford AP. P2X2 knockout mice and P2X2/ P2X3 double 
knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of 
ATP. J Physiol. 2005; 567(Pt 2):621–639.10.1113/jphysiol.2005.088435 [PubMed: 15961431] 
74. Vlaskovska M, Kasakov L, Rong W, Bodin P, Bardini M, Cockayne DA, Ford AP, Burnstock G. 
P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001; 
21(15):5670–5677. [PubMed: 11466438] 
75. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, 
Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP. Urinary 
bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000; 
407(6807):1011–1015.10.1038/35039519 [PubMed: 11069181] 
76. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in 
the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 
2004; 63(3 Suppl 1):17–23.10.1016/j.urology.2003.11.003 [PubMed: 15013648] 
77. Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ. A prospective evaluation of 
detrusor ultrastructural changes in bladder outlet obstruction. BJU Int. 2003; 91(4):360–364. 
[PubMed: 12603415] 
78. Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Aging differentially modifies agonist-evoked mouse 
detrusor contraction and calcium signals. Age (Dordr). 2011; 33(1):81–88.10.1007/
s11357-010-9163-7 [PubMed: 20596785] 
Tyagi et al. Page 16









79. Murakami S, Yoshida M, Masunaga K, Maeda Y, Ueda S. Change in acetylcholine release from rat 
bladder with partial outlet obstruction. BJU Int. 2008; 101(5):633–639.10.1111/j.1464-410X.
2007.07325.x [PubMed: 18070174] 
80. McMurray G, Casey JH, Naylor AM. Animal models in urological disease and sexual dysfunction. 
Br J Pharmacol. 2006; 147(Suppl 2):S62–S79.10.1038/sj.bjp.0706630 [PubMed: 16465185] 
81. Gabella G. Structure of the intramural nerves of the rat bladder. J Neurocytol. 1999; 28(8):615–
637. [PubMed: 10851342] 
82. Gabella G, Davis C. Distribution of afferent axons in the bladder of rats. J Neurocytol. 1998; 27(3):
141–155. [PubMed: 10640174] 
83. Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding 
difficulty. Int J Urol. 2008; 15(11):981–985.10.1111/j.1442-2042.2008.02134.x [PubMed: 
18721208] 
84. Insel TR. From animal models to model animals. Biol Psychiatry. 2007; 62(12):1337–
1339.10.1016/j.biopsych.2007.10.001 [PubMed: 18054535] 
Tyagi et al. Page 17










Diabetes-induced urethral dysfunction contributes to incomplete voiding. In these 
experiments, striated sphincter activity was suppressed by α-bungarotoxin and NO-mediated 
urethral relaxation was suppressed by L-NAME. Diabetic rat shows significantly reduced 
urethral pressure profile compared with normal rat
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Schematic illustration for rat model of Iatrogenic UAB-induced by brief bilateral pelvic 
nerve crush in adult female rats with a straight micro-mosquito clamp
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Cystometric outcomes of bilateral pelvic nerve crush in female rats. Compared with sham 
group, the crush injury of pelvic nerves exhibited increases in PVR and decreases in 
maximum voiding pressure and voiding efficiency
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